Government Oks sale of locally-produced hemophilia A treatment

Published: 2010-08-04 06:58:00

Updated: 2010-08-04 06:58:00

Korea’s health authorities gave the green light to Green Cross Corp. on August 30 to sell Greengene-F injection, an albumin-free, B-domain deleted (BDD) recombinant human coagulation factor VIIIB domain VIII.

It is the third medicine to treat hemophilia A following those developed by companies...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK